One pill to tackle two heart risks: new combo drug enters final testing
NCT ID NCT06643130
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether a new combination drug (JW0104+C2402) can safely lower both blood pressure and LDL cholesterol in people with hypertension and dyslipidemia. 162 participants will take the drug once daily for 8 weeks. The study is randomized and double-blind, meaning neither patients nor doctors know who gets which treatment, to ensure fair results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JW0104+C2402 (a combination drug taken by mouth once daily)
What this could lead to
If successful, this could offer a new once-daily pill that treats both high blood pressure and high cholesterol at the same time, simplifying treatment for patients.
What could go wrong
This is a mid-stage trial with only 162 people over 8 weeks, so results may not apply to everyone. The drug may not work better than existing options or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gangdong Sacred Heart Hospital
RECRUITINGSeoul, 05355, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••